CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
Sulforaphanedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05153174
NCT05153174Phase 1Completed
CompareCT.gov

Safety, Feasibility and Efficacy of Sulforaphane (Avmacol) in Chronic Kidney Disease

University of Rochester·interventional·Posted Dec 10, 2021·Updated Aug 12, 2024

In Brief

A Phase 1 clinical trial evaluating Sulforaphane for Chronic Kidney Disease stage3 and Chronic Kidney Disease stage4. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The purpose of this study is to test the safety of the compound sulforaphane that boosts the activity of antioxidant genes in the body to combat oxidative stress. Oxidative stress has been shown experimentally to play a role in kidney disease. This drug has been tested in patients with breast cancer who have normal kidney function, but has never been tested in patients with kidney disease. In this study, the investigators will establish a safe dose for patients with chronic kidney disease based on blood levels achieved in patients with normal kidney function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease stage3, Chronic Kidney Disease stage4
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedDec 10, 2021
Enrollment StartMay 2, 2022
Primary CompletionMay 25, 2023
Study CompletionJun 8, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.6 years ago

Interventions

Sulforaphanedrug

This is an over-the counter nutritional supplement. Participants will be given the extra strength tablets.